{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 2:', 'Schedule of Activities: Extension Period (Continued)', \"l'Trough (T) blood samples for serum PK, free C5 (PD), and ADA will be collected predose (within 30 minutes prior to the start of infusion of study drug). Peak\", '(P) blood samples for serum PK/PD are to be taken within the 30 minutes following completion of study drug infusion. The T samples may be drawn through', \"the venous access created for the dose infusion, prior to administration of the dose. The P samples will be drawn from the patient's opposite, noninfused arm.\", 'On Day 183 (Week 26), the T sample is considered a Randomized-Controlled Period assessment and the P sample is considered an Extension Period', 'assessment. All collection times will be recorded in eCRF. In the event of Clinical Deterioration, a blood sample for serum PK/PD and ADA analyses will be', 'collected if supplemental dosing is provided (see Section 8.1.2).', '12Patients will be given a Patient Safety Information Card prior to the first dose of study drug. At each visit throughout the study, staff will ensure that the patient', 'has the Patient Safety Information Card.', '13Ravulizumab will be administered intravenously via infusion after completion of all other tests and procedures, excluding the peak blood sampling for PK,', 'free C5, and ADA.', 'Abbreviations: AChR Ab = Acetylcholine receptor antibody; ADA = Antidrug antibody B = Baseline sample; C5 = Complement component 5;', 'C-SSRS = Columbia-Suicide Severity Rating Scale; ECG = electrocardiogram; EOS=End of Study; EQ-5D-5L = Euro Quality of Life; ET = Early Termination;', 'ICU = Intensive Care Unit; MG = Myasthenia Gravis; MG-ADL = MG Activity of Daily Living profile; MGC = Myasthenia Gravis Composite score;', 'MGFA = Myasthenia Gravis Foundation of America; MGFA-PIS = MGFA-Post-Intervention Status; N meningitidis = Neisseria meningitidis; P = peak sample;', 'PK/PD = pharmacokinetics/pharmacodynamics; QMG = Quantitative Myasthenia Gravis score for disease severity; QoL = quality of life; T = trough sample.', 'Page 25 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', '2.', 'INTRODUCTION', '2.1.', 'Generalized Myasthenia Gravis', 'Generalized myasthenia gravis (gMG) is a rare disorder, which based on studies conducted in', 'Europe, has an estimated prevalence between 145 to 278 per million inhabitants (Cetin, 2012;', 'Fang, 2015; Heldal, 2009). Patients with gMG suffer from a devastating inflammatory', 'neuromuscular disorder with limited therapeutic options.', 'Generalized myasthenia gravis patients differ from the ocular myasthenia gravis (MG)', 'population in that neuromuscular inflammation and the resultant clinical findings are not just', 'limited to the ocular muscles, but involve all voluntary muscle groups: the bulbar, respiratory,', 'head, neck, trunk, or peripheral muscles with or without involvement of the eyes. Profound', 'weakness and devastating consequences, including slurred speech, dysarthria, dysphagia,', 'disorienting vision, shortness of breath (both with activity and at rest), weakness of the upper and', 'lower extremities, impaired mobility, marked reductions in the ability to perform activities of', 'daily living (ADLs), extreme fatigue, and episodes of pulmonary failure requiring mechanical', 'ventilation are hallmarks of gMG. Compared with patients with isolated ocular MG, patients', 'with gMG have a greater incidence of morbidities and a higher burden of disease (Engel-Nitz,', '2018).', 'Hospitalizations for gMG exacerbations are common, with the need for respiratory support,', 'including mechanical ventilation secondary to respiratory failure (eg, myasthenic crisis) and', 'gastrointestinal tube placement for nutritional support and prevention of dysphagia-associated', 'aspiration. Patients with more advanced gMG have been reported to experience increased', 'mortality of up to 40% at 10 years following diagnosis (Christensen, 1998).', '2.2.', 'Background', '2.2.1.', 'Unmet Medical Need in Patients With Generalized Myasthenia Gravis', 'In difficult-to-control cases, patients with gMG experience unrelenting inflammation, tissue', 'destruction, and consequent severe morbidities including profound muscle weakness, impaired', 'mobility, shortness of breath, pulmonary failure, extreme fatigue, risk for aspiration, and', 'markedly impaired ADLs (Sahashi, 1978; Silvestri, 2014; Suh, 2013). These patients are', 'typically diagnosed in the prime of their adult lives, with a median age of onset ranging from', '36 to 60 years (Suh, 2013). As a result of the morbidities associated with gMG, many patients', 'cannot work or have diminished work-capacity, experience difficultly caring for themselves and', 'others, and require assistance speaking, eating, ambulating, breathing, and performing ADLs.', '2.2.2.', 'Role of Complement in Myasthenia Gravis', 'Uncontrolled terminal complement activation has been implicated in animal models of', 'experimental autoimmune gMG (Sahashi, 1978; Fitch, 1999; Dalakas, 2004; Keshavjee, 2005;', 'Patel, 2005) as well as in other forms of autoimmune neuropathy in humans. Autoantibodies', 'recognize targeted neural or muscle tissues, including the acetylcholine receptor (AChR), leading', 'to uncontrolled terminal complement activation at the neural or muscle surface (Ha, 2015).', 'Page 26 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}